AI in Medicine News — 2026-10-18 (Sun)

Overview

Activity was spread across diagnostics, clinical decision support, drug discovery and device regulation. Most items are research or market reports, and the headlines rarely state the evidence stage. The one clear regulatory event is an FDA clearance for a breast cancer recurrence tool (Fierce Biotech).

Diagnostics and imaging

- AI graded ultrasound image quality with 95% accuracy in breast cancer screening. The headline gives no evidence stage or dataset (Bioengineer.org). - A dermoscopy-dominant fusion approach boosted skin lesion diagnosis. The headline does not state the accuracy or evidence stage (Bioengineer.org). - A systematic review maps the state of AI neuroimaging diagnosis (Bioengineer.org). - A market report says telepathology and AI will drive growth in digital slide scanners through 2035 (IndexBox).

Clinical decision support

- AI read tumor slides to predict melanoma gene mutations, which the headline says could offer faster targeted therapy triage. The evidence stage is not stated (Bioengineer.org). - A new AI risk score predicts long-term disability after stroke using routine blood tests. The evidence stage is not stated (Bioengineer.org). - A piece asks how far the hype around AI ECG reading has actually travelled into the clinic (Bioengineer.org). - A framework turns EEG signals into plain-language depression clues, with the AI explaining its output. The evidence stage is not stated (Bioengineer.org). - An AI tool aims to catch critically ill children sooner (Griffin Daily News). - Tshikululu and Dr Sophia are piloting AI-assisted care for underserved communities, a pilot-stage program (mydurban.co.za). 【Generative AI and clinical documentation】 - UCHealth's approach to change management and ROI tracking for its AI deployments was covered. The headline gives no figures (Healthcare IT News). 【Hospital operations and care delivery】 - AI can turn medication instructions into a plan for people too sick to track their medications. The headline gives no evidence or deployment details (WBAP). - AI learned to map stroke damage in 3D, which the headline says speeds critical treatment decisions. The evidence stage is not stated (Bioengineer.org). 【Drug discovery and clinical trials】 - Pfizer describes how AI is helping match patients to clinical trials faster. This is a company description and the headline gives no data (Pfizer). - AstraZeneca agreed a $40m AI drug discovery deal with insitro. The development stage is not stated (EMJ). - AI is entering RNA drug discovery, from small molecules to oligonucleotide therapeutics. The stage is not stated (Bioengineer.org). - A market report projects the AI in drug discovery market at USD 17.56 Billion by 2031, at a CAGR of 28.1% (MarketsandMarkets, Yahoo Finance).

Device approval and regulation

- Clearance: SimBioSys received FDA clearance for an Nvidia-powered, MRI-derived breast cancer recurrence tool (Fierce Biotech). - Clearance and approval: CurveBeam AI will host an investor webinar on October 21, 2026 covering its FDA clearance and China NMPA approval. The product is not named in the headline (Kalkine). - Framework (not a regulatory decision): a readiness framework for clinical translation of AI in PET/CT, covering the move from task-specific AI to multimodal foundation models (Bioengineer.org). - Trade proposal (not a device ruling): China proposes adding 40 AI, biotech and solar technologies to its export list (electronics.economictimes.indiatimes.com).

Safety, errors and bias

- A piece titled "Decoding next phase of AI in healthcare" appeared. The headline gives no specifics on safety, errors or bias (Medical Buyer). 【Research results (major journals)】 None of the items below is identified as a major-journal paper in its headline. - A piece covers AI's impact on depression. The headline gives no findings (Your Wyoming Link). - Engineers used AI and Reddit to identify potential side effects of an unapproved new GLP-1. This is a signal-detection approach from social media, and the evidence stage is not stated (Medical Xpress). - A piece reports that a medical journal team was dismissed to train its AI replacement (Tomorrow's Publisher).

Developments in Japan

- Incerto is pursuing security strengthening and AI adoption together, so that medical institutions can use generative AI while protecting confidential information (Niconico News). - China will tighten export controls on AI technology and will ban exports where the technology may be misused for cyberattacks (Jiji Medical). - US-based PacBio will supply a sequencing system for France's TychoBio in its AI drug discovery for rare diseases. The stage is not stated (Nikkei Biotech ONLINE).

Statements by key figures

No notable developments.